Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional

A study of how CagriSema works on appetite in people with excess body weight

This study is investigating a new medication, called CagriSema, and how it might help with appetite. It's designed for people who are overweight or have obesity. Researchers want to understand if CagriSema can help people feel less hungry and potentially lead to weight loss by studying its effects in the human body. This is an early-stage study, meaning it's one of the first times this drug is being tested in people. The aim is to gather information on how the drug works and its initial effects, rather than to confirm its long-term benefits or safety. It's a way to learn more about new potential treatments.

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Novo Nordisk A/S

Enrolment target

150

Start

12 Dec 2023

Obesity

What is this study about?

This study is about a new medication called CagriSema. Doctors and researchers are trying to understand how this medication affects the body, specifically looking at its impact on appetite. They are focusing on people who are living with overweight or obesity. Obesity is a condition where a person has too much body fat, which can affect their health.

At this early stage, the main goal is to learn how CagriSema works inside the human body. This includes understanding if it can change how hungry a person feels. Think of it like a scientist trying to understand how a new engine works in a car – they want to see all the different parts in action and how they influence each other. This is not a study to see if the drug can cure obesity, but rather to gain important early information about its effects.

Learning more about how new medications affect appetite is important because it could lead to new ways to help people manage their weight. Better understanding how these drugs work can help researchers develop more effective and safer treatments in the future for conditions like obesity.

Key takeaways

Study is about a new drug called CagriSema.
It aims to understand how CagriSema affects appetite.
Open to adults 18 and over who are overweight or have obesity.
It's an early-stage study to learn how the drug works in the body.
Participation involves regular clinic visits and health checks.

Who may be eligible?

This study is open to adults who are 18 years old or older. Both men and women can take part.

To be considered for this study, you will need to have a Body Mass Index (BMI) that falls within the range considered overweight or obese. The healthcare team will check your height and weight to work this out so you don't need to know your exact BMI beforehand.

There might be other specific health requirements or conditions that mean you can or cannot join. These will be discussed with you in detail by the study team if you are interested in taking part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a diagnosis of overweight or obesity?
Are you able to attend regular clinic appointments?
Are you comfortable potentially trying an experimental medication?

Answer every question to see your result.

What does participation involve?

If you decide to take part, the study team will first check if you are suitable. This will involve some medical checks and questions about your health. If you are eligible, you will receive the study medication, CagriSema, likely through injections. You'll have regular appointments at the clinic for health checks, to discuss how you're feeling, and to monitor your progress.

These visits might include blood tests, measurements of your weight and other body signs, and questions about your appetite and how the medication is affecting you. You will also have follow-up appointments after you stop taking the medication to make sure you are doing well.

The total duration of your involvement in the study, including all visits and the follow-up period, will be explained fully by the study team. They will tell you exactly how many visits to expect and how long each phase will last.

Potential risks and benefits

Taking part in a study like this might offer a chance to try a new investigational medication that is not yet widely available. While there are no guarantees, there is a potential that CagriSema could help you feel less hungry. However, it's possible you might not experience any direct benefit yourself. As with any new medication, there's a chance of side effects, which could be mild (like irritation at the injection site) or more serious. The study team will closely monitor you and explain all known possible risks. Remember, you can choose to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Germany

Common questions

What is obesity?

Obesity is a medical condition where you have too much body fat that can harm your health. It's often measured using something called Body Mass Index (BMI).

What is CagriSema?

CagriSema is a new medication that is still being researched. This study is trying to understand how it works, especially on appetite.

Will I lose weight on this study?

The main goal of this early study is to understand how the drug works on appetite, not specifically to cause weight loss. While feeling less hungry might lead to weight changes, it's not the primary aim of this phase.

Is this drug available to buy now?

No, CagriSema is an experimental medication and is not yet available for general use. It is still being tested in clinical studies.

What does a 'Phase I' study mean?

Phase I means it's one of the first times the drug is being given to people. The main aim is to check how safe it is and how it works in the body, rather than confirming its long-term benefits.